Key points are not available for this paper at this time.
To address the growing U.S. shortages of critical generic drugs, long-term remedies, both legislative and regulatory, must be considered. Some basic changes in generic-drug law and FDA practices and greater financial incentives for manufacturing generics may be key.
Bruce A. Chabner (2011) studied this question.